Nektar Therapeutics (NKTR) stock
NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$30.20−2.34 (-7.19%)
Close on Nov 20, 2026Market cap $1.03BP/E –Yield –
Nektar Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Nektar Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$208.68M. For fiscal 2025 it was -$208.68M. The highest annual figure on record is $703.98M in fiscal 2018.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$208.68M | – |
| FY2024 | Dec 31, 2024 | -$177.18M | – |
| FY2023 | Dec 31, 2023 | -$193.47M | – |
| FY2022 | Dec 31, 2022 | -$309.68M | – |
| FY2021 | Dec 31, 2021 | -$427.65M | – |
| FY2020 | Dec 31, 2020 | -$320.55M | – |
| FY2019 | Dec 31, 2019 | -$354.97M | -150.4% |
| FY2018 | Dec 31, 2018 | $703.98M | – |
| FY2017 | Dec 31, 2017 | -$90.09M | – |
| FY2016 | Dec 31, 2016 | -$123.42M | – |
| FY2015 | Dec 31, 2015 | -$84.28M | – |
| FY2014 | Dec 31, 2014 | -$151.98M | – |
| FY2013 | Dec 31, 2013 | -$42.62M | – |
| FY2012 | Dec 31, 2012 | -$140.34M | – |
| FY2011 | Dec 31, 2011 | -$123.46M | – |
| FY2010 | Dec 31, 2010 | -$87.33M | -474.0% |
| FY2009 | Dec 31, 2009 | $23.35M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$64.98M | – |
| Q3 FY2025 | Sep 30, 2025 | -$48.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$45.78M | – |
| Q1 FY2025 | Mar 31, 2025 | -$49.06M | – |
| Q4 FY2024 | Dec 31, 2024 | -$46.65M | – |
| Q3 FY2024 | Sep 30, 2024 | -$44.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$37.89M | – |
| Q1 FY2024 | Mar 31, 2024 | -$48.05M | – |
| Q4 FY2023 | Dec 31, 2023 | -$47.28M | – |
| Q3 FY2023 | Sep 30, 2023 | -$42.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$51.69M | – |
| Q1 FY2023 | Mar 31, 2023 | -$52.35M | – |
| Q4 FY2022 | Dec 31, 2022 | -$58.22M | – |
| Q3 FY2022 | Sep 30, 2022 | -$83.07M | – |
| Q2 FY2022 | Jun 30, 2022 | -$75.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$92.63M | – |
| Q4 FY2021 | Dec 31, 2021 | -$157.43M | – |
| Q3 FY2021 | Sep 30, 2021 | -$104.07M | – |
| Q2 FY2021 | Jun 30, 2021 | -$86.18M | – |
| Q1 FY2021 | Mar 31, 2021 | -$79.96M | – |
| Q4 FY2020 | Dec 31, 2020 | -$100.39M | – |
| Q3 FY2020 | Sep 30, 2020 | -$54.59M | – |
| Q2 FY2020 | Jun 30, 2020 | -$86.60M | – |
| Q1 FY2020 | Mar 31, 2020 | -$78.98M | – |
| Q4 FY2019 | Dec 31, 2019 | -$128.89M | – |
| Q3 FY2019 | Sep 30, 2019 | -$73.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$65.57M | -106.9% |
| Q1 FY2019 | Mar 31, 2019 | -$86.54M | – |
| Q4 FY2018 | Dec 31, 2018 | -$126.24M | – |
| Q3 FY2018 | Sep 30, 2018 | -$73.23M | -179.5% |
| Q2 FY2018 | Jun 30, 2018 | $956.90M | – |
| Q1 FY2018 | Mar 31, 2018 | -$53.45M | – |
| Q4 FY2017 | Dec 31, 2017 | -$82.79M | – |
| Q3 FY2017 | Sep 30, 2017 | $92.14M | – |
| Q2 FY2017 | Jun 30, 2017 | -$60.78M | – |
| Q1 FY2017 | Mar 31, 2017 | -$38.66M | – |
| Q4 FY2016 | Dec 31, 2016 | -$55.06M | – |
| Q3 FY2016 | Sep 30, 2016 | -$27.87M | – |
| Q2 FY2016 | Jun 30, 2016 | -$15.16M | – |
See a number that looks wrong?